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Milan Gupta9,12,15, Bobby Yanagawa1,5,8, Mohammed Al-Omran3,5,8,11, Nandini Gupta16, Hwee Teoh1,4,5,6
and Jan O. Friedrich6,7,9,10*Abstract
Background: We assessed the effectiveness of dual antiplatelet therapy (DAPT) post elective or urgent (i.e., post
acute coronary syndrome [ACS]) coronary artery bypass graft surgery (CABG).
Methods: We systematically searched MEDLINE, EMBASE, and the Cochrane Registry from inception to August
2015. Randomized controlled trials (RCTs) in adults undergoing CABG comparing either dual vs. single antiplatelet
therapy or higher- vs. lower-intensity DAPT were identified.
Results: Nine RCTs (n = 4,887) with up to 1y follow-up were included. Five RCTs enrolled patients post-elective
CABG (n = 986). Two multi-centre RCTs enrolled ACS patients who subsequently underwent CABG (n = 2,155). These
7 RCTs compared clopidogrel plus aspirin to aspirin alone. Two other multi-centre RCTs reported on ACS patients
who subsequently underwent CABG comparing higher intensity DAPT with either ticagrelor (n = 1,261) or prasugrel
(n = 485) plus aspirin to clopidogrel plus aspirin. Post-operative anti-platelet therapy was started when chest tube
bleeding was no longer significant, typically within 24–48 h. There were no differences in all-cause mortality in
clopidogrel plus aspirin vs. aspirin RCTs; conversely, all-cause mortality was significantly lower in ticagrelor and
prasugrel vs. clopidogrel RCTs (risk ratio[RR] 0.49, 95 % confidence interval[CI] 0.33–0.71, p = 0.0002; 2 RCTs, n = 1695;
I2 = 0 %; interaction p < 0.01 compared to clopidogrel plus aspirin vs aspirin RCTs). There were no differences in
myocardial infarctions, strokes, or composite outcomes. Overall, major bleeding was not significantly increased
(RR 1.31, 95 % CI 0.81–2.10, p = 0.27; 7 RCTs, n = 4500). There was heterogeneity (I2 = 42 %) due almost entirely to
higher bleeding reported for the prasugrel RCT which included mainly CABG-related major bleeding (RR 3.15, 95 %
CI 1.45–6.87, p = 0.004; 1 RCT, n = 437).
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Conclusions: Most RCT data for DAPT post CABG is derived from subgroups of ACS patients in DAPT RCTs
requiring CABG who resume DAPT post-operatively. Limited RCT data with heterogeneous trial designs suggest that
higher intensity (prasugrel or ticagrelor) but not lower intensity (clopidogrel) DAPT is associated with an
approximate 50 % lower mortality in ACS patients who underwent CABG based on post-randomization subsets
from single RCTs. Large prospective RCTs evaluating the use of DAPT post-CABG are warranted to provide more
definitive guidance for clinicians.
Keywords: Coronary artery bypass graft surgery, Acute coronary syndrome, Anti-platelet therapy, P2Y12 antagonists,
Systematic review, Meta-analysisBackground
Dual antiplatelet therapy (DAPT) with acetylsalicylic
acid (ASA) and an oral P2Y12 antagonist, is the corner-
stone for management of patients presenting with acute
coronary syndrome (ACS). Although there are no rec-
ommendations regarding DAPT treatment post elective
CABG, guidelines recommend that therapy with DAPT
be continued for one year following ACS (non-ST segment
elevation myocardial infarction [NSTEMI], ST-elevation
myocardial infarction [STEMI] or unstable angina), irre-
spective of whether patients are managed medically or in-
vasively with either percutaneous coronary intervention or
coronary artery bypass graft (CABG) surgery [1, 2]. The
evidence supporting the benefit of DAPT in ACS pa-
tients has been based largely on three landmark trials,
namely CURE [3], TRITON-TIMI 38 [4] and PLATO
[5]. Whereas cardiac surgeons are well versed with the
guidelines regarding discontinuation of DAPT prior to
CABG to minimize bleeding risks [6, 7], there is con-
siderable variability in DAPT resumption in ACS pa-
tients post CABG [8–10]. Since only a small proportion
of patients in large trials undergo CABG, individual
RCTs have not been adequately powered to address the
role of DAPT in the post-CABG cohort. We therefore,
conducted a meta-analysis of RCTs to evaluate the ben-
efits of DAPT resumption in post CABG patients, ei-
ther elective or post ACS, using all-cause mortality as
the pre-specified primary endpoint.Methods
Data sources
We systematically searched OVID versions of MEDLINE
(1946 through to August 2015, week 2), EMBASE
Classic and EMBASE (1947 through 2015 week 34),
and the Cochrane Central Register of Controlled Trials
(July 2015) for relevant studies using search terms for
anti-platelet agents and coronary artery bypass surgery,
and published sensitive filters to identify randomized
controlled trials (RCTs) (Fig. 1). We also searched
bibliographies of included studies and personal files.
We did not impose language restrictions.Study Selection
We included prospective clinical trials randomizing
adult patients with coronary artery disease undergoing
CABG either 1) to dual vs single antiplatelet therapy
(e.g., clopidogrel plus ASA vs ASA alone) or 2) to higher
vs lower intensity dual antiplatelet therapy (e.g., ticagre-
lor or prasugrel plus ASA vs clopidogrel plus ASA). To
meet inclusion criteria, RCTs had to either include only
patients undergoing CABG, or report outcomes separ-
ately in subgroups of patients with ACS who underwent
CABG. Studies were excluded if patients were not ran-
domized between treatment groups or if outcomes were
not reported separately for patients undergoing CABG.
Citations were screened in duplicate and full text review
was conducted to determine eligibility when either
screening reviewer felt a citation potentially met inclu-
sion criteria.
Data Extraction and Quality Assessment
Details of the publication (i.e., trial authors and acro-
nym, enrolment period, year of publication), inclusion/
exclusion criteria, demographics and cardiac risk factors
of the enrolled patients, description of the interventions
used, and outcome definitions and events were collected
and collated. Risk of bias in RCTs (including blinding of
participants, method of sequence generation and alloca-
tion concealment, intention-to-treat analysis, early trial
stopping for efficacy before the planned enrollment was
completed, and loss to follow-up) was also assessed.
Data Analysis
Our primary hypothesis was that all-cause mortality at
the longest duration of follow up is decreased in patients
undergoing CABG randomized to dual antiplatelet ther-
apy vs patients randomized to lower intensity dual or
single antiplatelet therapy. Secondary outcomes, also at
the longest duration of follow up, included non-fatal
myocardial infarction (MI); non-fatal stroke; the com-
posite outcome of cardiovascular (alternatively all-cause)
mortality or non-fatal MI or non-fatal stroke; and bleed-
ing (major bleeding, preferably non-CABG related, if
Fig. 1 Search strategy and trial flow. Flow chart for the systematic review and meta-analysis showing the search strategy, and the number of
studies retained and number of studies excluded with reason for exclusion at each stage of the study selection process [72–78]
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lysis included all patients in an intention to treat analysis.
Prespecified subgroup analyses were conducted compar-
ing 1) dual vs single antiplatelet therapy trials in elective
CABG patients, to 2) dual vs single antiplatelet therapy
trials in ACS patients who underwent CABG, to 3) higher
intensity vs lower intensity dual antiplatelet trials in ACSpatients who underwent CABG. We planned to also con-
duct a supplementary “on treatment” analysis including
only patients who were actually continued on study drugs
post-operatively, but these data were only available for one
outcome (mortality) for one trial [11]. All meta-analyses
were performed using Review Manager (RevMan version
5.2; Cochrane Collaboration, Oxford, UK) by one of the
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orate between-trial heterogeneity and give wider and more
conservative confidence intervals (CI) when heterogeneity
is present were used for all analyses. Statistical heterogen-
eity among trials was assessed using I2, defined as the per-
centage of total variability across studies attributable to
heterogeneity rather than chance, and using published
guidelines for low (I2 = 25 %–49 %), moderate (I2 = 50 %–
74 %) and high (I2 ≥ 75 %) heterogeneity [13]. Risk ratios
(RR) were used to pool outcomes with a two-sided signifi-
cance level of 5 %. Individual trial and summary results
are reported with 95 % CIs. Differences between pooled
RRs were evaluated using z tests. To assess for publication
bias, a funnel plot comparing effect measure for the pri-
mary outcome of mortality to study precision was exam-
ined for evidence of asymmetry. Further more formal
statistical testing for funnel plot asymmetry was not carried
out due to the low number of RCTs meeting inclusion cri-
teria (<10) which would result in low statistical power to
distinguish chance from real asymmetry [14].
We contacted authors of included trials to clarify out-
come data when required. Authors of one trial provided
the numbers of patients who sustained myocardial in-
farctions and informed us that rates of stroke were not
measured [15]. For the remainder we were informed that
no additional data were available [11, 16–18]. For two
ACS trials only the composite outcome of either cardio-
vascular [19] or all-cause mortality [18], MI, and stroke
were reported for the subgroup of patients who under-
went CABG. Authors of one of these trials provided indi-
vidual event rates [19]. For the other trial, we estimated
all-cause mortality, MI, and stroke rates assuming the
same overall ratios of the separate outcomes to the com-
posite outcome for each randomized group as reported in
the main trial publication [20].
Results
The initial search strategy yielded 2148 citations from
MEDLINE and EMBASE, and 222 citations from Cochrane,
of which 40 were retrieved for full text review. Nine RCTs
met inclusion criteria (Fig. 1) [11, 15–19, 21–23]. Details
regarding excluded RCTs are provided in Additional file
1: Table S1. In brief, RCTs in patients post elective
CABG were excluded if no outcome events occurred or
were reported [24–30] (including duplicate publication
[31]) or single anti-platelet therapies were used in both
randomized groups [32–35] (including duplicate publi-
cations [36, 37]). RCTs enrolling patients with ACS
were excluded if no separate outcome data was avail-
able for the subgroup of patients who underwent
CABG (CHARISMA [38], DISPERSE-2 [39], COMMIT
[40], TRILOGY ACS [41], and JUMBO-TIMI 26 [42]),
patients were not treated with dual-antiplatelet therapy
post CABG (CLARITY-TIMI 28 [43] and CURRENTOASIS 7 [44]), trials reported only on patients previ-
ously treated with CABG but not during the study
period (CAPRIE [45] and PLATO [46]); or patients were
randomized to a non-P2Y12 antagonist (TRACER [47]).
One RCT in elective CABG patients was ongoing [48].
Description of Included Studies and Quality Assessment
Table 1 provides details of the trials including baseline
patient characteristics. Of the 9 included RCTs, five were
single- [15, 16, 22, 23] or two-centre [21] RCTs that en-
rolled patients post elective CABG and compared clopi-
dogrel plus ASA to ASA alone. One trial specified that
ASA was not held pre-operatively [21]. ASA and clopi-
dogrel were restarted post-operatively when chest tube
bleeding was no longer significant, typically within 24–
48 h. Patients were randomized either pre- [16] or post-
[15, 21, 22] operatively. In one trial [23], patients were
randomized on postoperative day 4 while on aspirin to
clopidogrel add on but only if found to be aspirin resist-
ant on aggregometry-based assessment.
The other four RCTs were all large multicentre trials
enrolling patients with ACS that reported data separately
for the subgroup of patients who underwent CABG [11,
17–19]. Of the ACS trials, 2 compared clopidogrel plus
ASA to ASA alone [3, 20], and 2 compared higher inten-
sity dual anti-platelet therapy with either ticagrelor [5]
or prasugrel [4] plus ASA vs clopidogrel plus ASA.
CREDO [20] enrolled patients who were referred for cor-
onary angiography with symptomatic coronary artery dis-
ease (angina pectoris, positive stress test, or dynamic
electrographic changes). CURE [3] enrolled patients with
acute ischemic symptoms and either electrographic
changes and/or elevation of cardiac enzymes to indicate
myocardial necrosis, but excluded patients with ST eleva-
tion. Both PLATO [5] and TRITON-TIMI 38 [4] had
similar inclusion criteria and allowed patients with either
ST depression or ST elevation ACS. In TRITON-TIMI 38
[4] the coronary anatomy had to be defined and suitable
for percutaneous coronary intervention (PCI) before
randomization, hence a smaller percentage of patients
progressed to CABG in this trial. In three of the included
ACS trials [3–5], ASA and blinded second anti-platelet
therapies were started shortly after presentation, whereas
for CREDO [20] both randomized groups received dual
anti-platelet therapy with clopidogrel for the first 28 days
and then the control group received placebo for the re-
mainder of the 1 year treatment period. For patients sub-
sequently requiring CABG, the second anti-platelet
therapy or corresponding placebo was typically held be-
tween 1 and 7 days pre-operatively, and then re-started
post-operatively in the majority (62–76 %) of patients
(Table 1) [11, 17, 19]. For CURE [19] and CREDO [18]
outcome data was provided for all patients who under-
went CABG. For PLATO outcome data were provided
Table 1 Trial and Baseline Patient Characteristics, and Interventions
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Table 1 Trial and Baseline Patient Characteristics, and Interventions (Continued)
Prev MI 39 % 47 % n/r 36 % n/r 37 % 36 % 20 % n/r (18 %b)
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who received study drug within 7 days prior to the pro-
cedure [17]. For TRITON-TIMI 38 all outcome data were
only provided for the 346 of 485 randomized patients that
underwent CABG who received at least one dose of study
drug prior to the procedure [11]; additional outcome data
on all randomized patients that underwent CABG were
provided in a FDA presentation [49].
For all trials, enrolled patients had a mean age around
60 years old, were predominantly male, and had the ex-
pected prevalence of various coronary risk factors
(Table 1). 18–47 % of patients had previous myocardial in-
farction, and a small percentage (3–8 %) had previous
stroke. A small percentage also had previously been
treated with PCI or CABG. Patients with heart failure or
severe left ventricular dysfunction were generally excluded.
Some trials used off-pump surgery, and all patients re-
ceived multiple grafts with at least one arterial conduit.
As shown in Table 1, in the 5 RCTs enrolling elective
CABG patients, all patients were enrolled at the time of
CABG and followed up for 12 months in two trials [21, 22],
6 months in one trial [23], 3 months in one trial [15], and a
minimum of 30 days (median 49 days) in the fifth trial [16].
In 3 of the 4 RCTs enrolling ACS patients, CABG occurred
at a median time of 20–100 days post-randomization
[17, 19, 50] and patients were followed for a median of 6.7
to 11.2 months post CABG. Time to CABG and follow up
duration was similar between groups in each trial. The
fourth ACS trial enrolling patients expected to require PCI
did not specifically report time to CABG but included only
patients who were treated with CABG instead of PCI at
study enrolment implying treatment shortly after
randomization, and followed all patients for 12 months
post randomization [18]. For all trials only clinical out-
comes that occurred post CABG were included.
Study quality was relatively high (Table 2). Allocation
was concealed in all trials except for one single-centre
trial where it was unclear [15], and all studies except for
three single-centre trials [15, 22, 23] blinded participantsTable 2 Quality assessment of included randomized controlled trials
Trial Blinded Concealed allocation Intention t
analysis
CURE [3, 19] Yes Yes (central randomization) Yes
PLATO [5, 17] Yes Yes (central randomization) Yes
TRITON-TIMI 38 [4, 11] Yes Yes (central randomization) Yes
CREDO [18, 20] Yes Yes Yes
CRYSSA [22] No Yes Yes
CASCADE [21] Yes Yes Yes
Gao 2010 [15] No Unclear Yes
Sun 2010 [16] Yes Yes Yes
Gasparovic 2014 [23] No Yes Yesusing placebos. All trials used intention-to-treat analysis,
were not stopped early for benefit, and had <5 % (and
for the large multi-centre trials ≤0.1 %) of randomized
patients with missing outcome data.
Quantitative Data Synthesis
All-Cause Mortality (Fig. 2): Pooling data from all RCTs,
there was no difference in all-cause mortality (RR 0.68,
95 % CI 0.43–1.08, p = 0.10) with some heterogeneity
(I2 = 39 %). The clopidogrel plus ASA vs ASA RCTs
showed no difference in all-cause mortality for either
the elective CABG (RR 0.56, 95 % CI 0.18–1.67, p = 0.29)
or the ACS CABG subgroups (RR 1.18, 95 % CI 0.83–
1.66, p = 0.36). However, the ticagrelor or prasugrel vs
clopidogrel RCTs showed significantly lower risk for all-
cause mortality (RR 0.49, 95 % CI 0.33–0.71, p = 0.0002).
There was no heterogeneity within any of the subgroups
(I2 = 0 %). The differences between the clopidogrel plus
ASA vs ASA elective CABG and ACS subgroups (either
individually or combined), and the ticagrelor or prasugrel
vs clopidogrel subgroup results were statistically signifi-
cant (interaction p-value 0.002–0.007). Visual inspection
of the funnel plot showed no evidence of asymmetry (data
not shown).
Other Clinical Outcomes: Neither dual vs single nor
higher-intensity vs lower-intensity dual anti-platelet
therapy resulted in decreased myocardial infarction (RR
0.91, 95 % CI 0.69–1.20, p = 0.52; Fig. 3a) or stroke (RR
1.10, 95 % CI 0.75–1.62, p = 0.61; Fig. 3b) with similar
non-significant treatment effects in the dual vs single
anti-platelet and higher-intensity vs lower-intensity
DAPT subgroups (I2 = 0 %). Likewise the composite out-
come of death from cardiovascular causes (all-cause
mortality for CRYSSA [22] and CREDO [18]), myo-
cardial infarction, and stroke (only cardiovascular
death and myocardial infarction for Gao 2010 [15])
remained non-significant (Fig. 3c): RR 0.86, 95 % CI
0.73–1.03, p = 0.10, with no differences in results be-
tween subgroups (I2 = 0 %).o treat Not stopped early
for benefit
< 5 % Randomized Patients with
Missing Outcome Data
Yes Yes (0.1 %: 13/12,562 overall; 0 % of CABG)
Yes Yes (0.03 %: 5/18,624 overall)
Yes Yes (0.1 %: 14/13,608 overall)
Yes Yes (0 %)
Yes Yes (0.3 %: 1/300)
Yes Yes (0 %)
Yes Yes (3.7 %: 9/249)
Yes Yes (1.0 %: 1/100)
Yes Yes (2.2 %: 5/224)
Fig. 2 Forest plot for all-cause mortality. Individual and pooled risk ratios (RR) with 95 % confidence intervals (CI) for randomized controlled trials
(RCTs) comparing dual anti-platelet therapy with clopidogrel and ASA to single anti-platelet therapy with ASA alone either after elective coronary
artery bypass graft surgery (CABG) [15, 16, 21–23] or in patients with acute coronary syndrome (ACS) who subsequently underwent CABG [18, 19],
and RCTs comparing higher to lower intensity dual anti-platelet therapy with either ticagrelor [17] or prasugrel [11] and ASA vs clopidogrel and
ASA in patients with ACS who subsequently underwent CABG. The pooled RRs with 95 % CI were calculated using random-effects models both
overall and for each subgroup. Weight refers to the contribution of each study to the overall pooled estimate of treatment effect. Each square
and horizontal line denotes the point estimate and 95 % CI for each trial’s RR. The diamonds signify the pooled RR for all trials and each subgroup; the
diamond’s centre denotes the point estimate and width denotes the 95 % CI. For CREDO, the number of all-cause deaths was estimated using the
ratio of this outcome to the composite outcome for each randomized group reported in the main trial publication [20] because the ACS CABG
publication [18] for this trial only provided composite outcomes
Verma et al. BMC Surgery  (2015) 15:112 Page 9 of 15Bleeding: The clopidogrel plus ASA vs ASA trials
that reported bleeding used CURE trial [19, 21, 22],
Bleeding Academic Research Consortium (BARC)
Bleeding Definitions [51] Type 3–5 [23] or similar
[16] criteria for major bleeding and reported events
that were either non-CABG related [16, 21–23] or
more than 7 days post CABG [19]. The higher-
intensity vs lower-intensity DAPT trials reported
bleeding using TIMI criteria and included both
CABG-related and non-CABG-related bleeding. One
of these trials specifically stated that “nearly all bleed-
ing events occurred within 24 h post-CABG” [17].
Overall, major bleeding was not significantly increased
(RR 1.31, 95 % CI 0.81–2.10, p = 0.27; Fig. 4) with
some heterogeneity (I2 = 42 %) but no differences be-
tween subgroup results. The heterogeneity was due
entirely to the significantly higher bleeding rate re-
ported for TRITON-TIMI 38 (I2 = 0 % when the re-
sults of this trial are excluded).Discussion
The results from this analysis suggest that DAPT re-
sumption with higher intensity P2Y12 antagonists (prasu-
grel or ticagrelor), but not clopidogrel reduces all-cause
mortality in ACS patients who have undergone CABG.
However, these results are based on post-randomization
subsets from single RCTs where DAPT was initiated
prior to CABG, with the intention of continuing therapy
for one year post revascularization. Although it would
have been invaluable to compare the outcomes in pa-
tients who continued DAPT vs. those in whom therapy
was not resumed post-CABG, these data were not avail-
able. Likewise, there are no RCTs wherein ACS patients
were randomized to receive DAPT vs. ASA following
CABG. Finally, the number of patients enrolled in elect-
ive CABG RCTs was considerably smaller, and the
pooled results of these RCTs comparing exclusively clo-
pidogrel plus ASA to ASA alone post operatively dem-
onstrated no differences in outcomes.
Fig. 3 (See legend on next page.)
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Fig. 3 Forest plot for (a) myocardial infarction, (b) stroke, (c) composite outcome including cardiovascular mortality, myocardial infarction, and stroke.
Individual and pooled risk ratios (RR) with 95 % confidence intervals (CI) for randomized controlled trials (RCTs) comparing dual anti-platelet therapy
with clopidogrel and ASA to single anti-platelet therapy with ASA alone either after elective coronary artery bypass graft surgery (CABG) [15, 16, 21–23]
or in patients with acute coronary syndrome (ACS) who subsequently underwent CABG [18, 19], and RCTs comparing higher to lower intensity dual
anti-platelet therapy with either ticagrelor [17] or prasugrel [11] and ASA vs clopidogrel and ASA in patients with ACS who subsequently underwent
CABG. The pooled RRs with 95 % CI were calculated using random-effects models both overall and for each subgroup. Weight refers to the
contribution of each study to the overall pooled estimate of treatment effect. Each square and horizontal line denotes the point estimate and
95 % CI for each trial’s RR. The diamonds signify the pooled RR for all trials and each subgroup; the diamond’s centre denotes the point estimate and
width denotes the 95 % CI. For CREDO, the number of myocardial infarctions and strokes was estimated using the ratio of this outcome to the
composite outcome for each randomized group reported in the main trial publication [20] because the ACS CABG publication [18] for this trial only
provided composite outcomes. For the composite outcome reported in Panel C, only all-cause mortality was available for CRYSSA 2012 [22] and
CREDO [18], and only cardiovascular death and myocardial infarction for Gao 2010 [15]
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it is important to highlight that in TRITON-TIMI 38
prasugrel was only initiated after the coronary anatomy
was defined and PCI was planned [11]. The trial was not
intended to recruit patients destined for CABG,
although in the minority of patients who did undergo
CABG, the prasugrel group yielded a significantFig. 4 Forest plot for major bleeding. Individual and pooled risk ratios (RR)
(RCTs) comparing dual anti-platelet therapy with clopidogrel and ASA to si
artery bypass graft surgery (CABG) [16, 21–23] or in patients with acute cor
RCTs comparing higher to lower intensity dual anti-platelet therapy with ei
in patients with ACS who subsequently underwent CABG. The pooled RRs
and for each subgroup. Weight refers to the contribution of each study to the
line denotes the point estimate and 95 % CI for each trial’s RR. The diamonds
centre denotes the point estimate and width denotes the 95 % CI. The clopid
Academic Research Consortium (BARC) Type 3–5 [23] (all BARC Type 3 for this
[16] criteria for major bleeding and reported events that were either non-
higher-intensity vs lower-intensity dual anti-platelet PLATO [17] and TRITO
CABG related bleeding which made up the vast majority of the bleeding
ACS CABG patients in these RCTs). If TIMI criteria are used for the CURE tr
CI 0.71–2.19, p = 0.43; I2 = 48 %). Excluding TRITON TIMI 38 [11] from the preduction in mortality. Prasugrel was associated with an
increased risk of major bleeds which was primarily
CABG related. A subsequent analysis by the trial authors
indicated that prasugrel-treated patients received higher
platelet but not red blood cell transfusions [50].
Ticagrelor is a novel P2Y12 antagonist, with a reversible
mechanism of action. It provides more effective andwith 95 % confidence intervals (CI) for randomized controlled trials
ngle anti-platelet therapy with ASA alone either after elective coronary
onary syndrome (ACS) who subsequently underwent CABG [19], and
ther ticagrelor [17] or prasugrel [11] and ASA vs clopidogrel and ASA
with 95 % CI were calculated using random-effects models both overall
overall pooled estimate of treatment effect. Each square and horizontal
signify the pooled RR for all trials and each subgroup; the diamond’s
ogrel plus ASA vs ASA trials used either CURE trial [19, 21, 22], Bleeding
trial [i.e., no CABG-related {Type 4} or fatal {Type 5} bleeding]), or similar
CABG related [16, 21–23] or more than 7 days post CABG [19]. The
N-TIMI 38 trials reported bleeding using TIMI criteria and included
events (non-CABG related bleeding data was not available for the
ial [19], the pooled results are essentially unchanged (RR 1.25, 95 %
ooled results eliminates the heterogeneity (I2 = 0 %)
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grel [52], and recent data suggest that it may also have a
unique pleiotropic effect to augment adenosine bioavail-
ability [53]. In the PLATO trial, randomization for 1-year
to DAPT with ticagrelor vs. clopidogrel reduced all-cause
mortality in the entire cohort by 20 %; the magnitude of
benefit was particularly striking in those who underwent
CABG (of whom approximately 66 % were restarted on
study drug), where an approximate 50 % reduction in
mortality was observed [17]. Interestingly, CABG related
major bleeding, defined by various criteria was not differ-
ent between ticagrelor vs. clopidogrel arms, and neither
were the rate of transfusion or mean chest tube drainage.
However, non-CABG related major bleeds were slightly
higher in the ticagrelor vs. clopidogrel treated patients in
all patients [5]. (Non-CABG related major bleed data was
unfortunately unavailable for the CABG subset [17]).
Since non-CABG related bleeding is likely the safety out-
come of interest outside of the immediate perioperative
period, surgeons must weigh the bleeding risk relative to
the major reduction in all-cause mortality in choosing
whether or not to resume DAPT with ticagrelor [54]. Re-
cent data suggest that the adjusted hazard ratio for bleed-
ing with ticagrelor does not increase with age [55].
The present analysis does not provide insight regarding
what types of ACS patients are more likely to benefit from
DAPT post CABG. It may be hypothesized that patients
with diffuse disease (diabetes and chronic kidney disease
for example), may be more likely to derive ongoing ische-
mic benefit by virtue of reduction in new atherothrombotic
events. Likewise, analysis of benefit as a function of com-
plexity of lesions (SYNTAX score for example) has not
been conducted. Individualizing therapy based on residual
platelet reactivity while on treatment which can vary widely
between patients may help to better identify patients who
would benefit from higher intensity anti-platelet therapy.
For example, the most recently published trial included in
this meta-analysis [23] attempted to do this by randomizing
only patients to DAPT who still had high residual platelet
reactivity while on ASA. Further studies aimed at better re-
fining the subgroups that are more likely to derive the
greatest ischemic benefit, and yield the lowest bleeding sig-
nal need to be performed.
Our systematic review and meta-analysis is the first to
include both RCTs enrolling patients undergoing elective
CABG and subgroups of patients presenting with ACS
who subsequently require CABG. Furthermore, we also
included RCTs that employed both higher- and lower-
intensity dual antiplatelet therapies. Because results from
these different types of RCTs may differ, we separated
them into subgroups of RCTs for each analysis to high-
light potential differences. Previous systematic reviews
have been more restrictive either including only studies
enrolling elective CABG patients [56–58], comparinglower intensity dual antiplatelet therapy with clopidogrel
plus ASA to ASA [59], comparing dual or single anti-
platelet therapy with clopidogrel to ASA [60, 61], or
comparing higher- to lower-intensity dual anti-platelet
therapy [62, 63]. These systematic reviews are in
addition to those evaluating the use of dual anti-platelet
therapy at the time of CABG [64–71]. We included all
RCTs in any of these systematic reviews that met inclu-
sion criteria for the current review.
Study Limitations
Although we used rigorous systematic review and meta-
analytic methods consistent with PRISMA guidelines in-
cluding a reproducible and comprehensive literature
search strategy, clearly defined inclusion criteria, dupli-
cate citation review, data abstraction, and quality assess-
ment of individual studies, and a pre-defined analysis
plan, we pooled results from studies that employed dif-
ferent inclusion/exclusion criteria, interventions, and fol-
low up periods. In particular, we pooled results from
trials comparing dual vs single antiplatelet therapies
(clopidogrel plus ASA vs ASA) with trials using different
higher intensity dual platelet therapies (using ticagrelor
or prasugrel) vs lower intensity dual platelet therapies
(using clopidogel). We also pooled results from trials en-
rolling elective CABG patients with ACS patients who
were randomized to dual anti-platelet therapy groups
and then subsequently required CABG. Recognizing
these differences, we presented pooled results separately
for each of these subgroups within each analysis. The
small size of elective CABG patient trials resulted in few
events highlighting the paucity of currently available
data (as well as upcoming data from ongoing registered
trials listed in Additional file 1: Table S1) in this specific
patient population, making it difficult to assess either
the benefits, in terms of reducing adverse cardiac events,
or the harms, in terms of increased bleeding. Follow up
duration was variable ranging from 1.5 to 12 months for
the elective CABG patients trials, and 6–12 months for
the trials enrolling ACS patients who subsequently re-
quired CABG. The majority of the patient data was
obtained from the large multicentre trials enrolling pa-
tients with ACS in which only a subgroup of patients
underwent CABG [11, 17–19], at various time points, up
to a median of 100 days post randomization in one trial
[50]. Although separate subgroup data for the patients
treated with CABG have been reported in the ACS RCTs,
the decision to undergo CABG is a post randomization
event occurring at variable times post randomization.
This decision can thus be influenced by randomized
group resulting in potential baseline imbalances be-
tween intervention and control groups within the sub-
group, though the baseline characteristics reported for
the subgroups undergoing CABG were balanced in
Verma et al. BMC Surgery  (2015) 15:112 Page 13 of 15these trials [11, 17–19]. Furthermore in some of these
trials, complete outcome data are only reported for
some of the patients who underwent CABG [11, 17]
and these patients may be lower risk than CABG ACS
patients treated outside of clinical trials. Except for
bleeding events in CURE which were reported greater
than 7 days post CABG, bleeding events in the other
ACS trials though reported postoperatively also in-
cluded events related to the operation. For example,
bleeding events in TRITON-TIMI 38 and PLATO in-
cluded all post-operative events and one of these re-
ports stated that “nearly all bleeding events occurred
within 24 h post-CABG” [17]. Finally, for the subgroups
of patients with acute coronary syndrome who under-
went CABG, we analyzed the patients on an intention
to treat basis; only 62–76 % of the patients in the three lar-
gest trials [11, 17, 19] resumed dual antiplatelet therapy
post operatively. Incomplete resumption of assigned treat-
ment will reduce apparent treatment and adverse effects.
Only TRITON-TIMI 38 provided on-treatment data and
then only for mortality [11]. Conducting an on-treatment
analysis, if these data were available for all trials, may
provide better efficacy data; however, this would involve
incorporating a further post-randomization event poten-
tially leading to non-comparable groups with dissimilar
baseline characteristics. For ACS patients the timing of
DAPT treatment is likely more complex since when
DAPT is discontinued preoperatively (to maximize the
ACS benefit and to minimize bleeding) and when DAPT
is resumed postoperatively (to maximize post-operative
benefits) may both potentially affect outcomes.
Conclusions
Based on the available but limited RCT data, resumption
of anti-platelet therapy post operatively with higher in-
tensity DAPT (prasugrel or ticagrelor with ASA) but not
lower intensity DAPT (clopidogrel and ASA) appears to
reduce all-cause mortality by about 50 % in patients with
ACS who undergo CABG. With the caveat that the data
are primarily based on retrospective subgroup analysis
from single RCTs of ACS patients who progress to
CABG, the net clinical benefit (efficacy vs. bleeding) ap-
pears to favour the use of ticagrelor in these patients.
No significant benefits or harms were detected for DAPT
after elective CABG, however, few such patients have been
studied in randomized trials. The limited RCT data sug-
gest that large prospective RCTs evaluating the use of
DAPT post-CABG are urgently needed to provide more
definitive guidance for clinicians.Additional file
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